Johnny Powers Net Worth

The estimated Net Worth of Johnny D Powers is at least $1.46 Million dollars as of 28 August 2024. Johnny Powers owns over 100,000 units of Zomedica Pharmaceuticals stock worth over $295,508 and over the last 16 years he sold ZOM stock worth over $1,161,935. In addition, he makes $0 as Independent Director at Zomedica Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Johnny Powers ZOM stock SEC Form 4 insiders trading

Johnny has made over 30 trades of the Zomedica Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of ZOM stock worth $13,000 on 28 August 2024.

The largest trade he's ever made was exercising 750,000 units of Zomedica Pharmaceuticals stock on 12 April 2021 worth over $337,500. On average, Johnny trades about 72,201 units every 120 days since 2009. As of 28 August 2024 he still owns at least 2,325,000 units of Zomedica Pharmaceuticals stock.

You can see the complete history of Johnny Powers stock trades at the bottom of the page.

Johnny Powers biography

Dr. Johnny D. Powers is Independent Director of the Company. Dr. Powers has more than 30 years of experience in the medical diagnostics industry, including over seven years of experience in veterinary healthcare as a senior executive at IDEXX Laboratories. Dr. Powers was Executive Vice President of IDEXX from July 2012 until February 2016, overseeing multiple business units, including IDEXX Reference Labs, Telemedicine Services, Rapid Assay Point-of-Care Products, Bioresearch and Worldwide Operations. He joined IDEXX as Corporate Vice President in February 2009, where he led IDEXX Reference Labs to a global leadership position. Prior to joining IDEXX, Dr. Powers was Vice President responsible for the Cancer Diagnostics business of Becton, Dickinson and Company, a medical technology company, from January 2007 to June 2008. Dr. Powers joined Becton, Dickinson and Company as a result of its acquisition in December 2006 of TriPath Imaging Inc., a molecular diagnostics-based cancer diagnostics company, where he held various senior management positions from November 2001 to January 2007, including Vice President of Worldwide Operations, and President of the TriPath Oncology business unit. From February 1996 to September 2001, Dr. Powers was employed by Ventana Medical Systems, Inc., a tissue-based cancer diagnostics company, where he held various positions, including Vice President and General Manager of the Anatomical Pathology business and Vice President and General Manager of Worldwide Operations. From June 1990 to February 1996, Dr. Powers was employed by Organon Teknika Corporation, a medical diagnostics company, in various technical management roles. Dr. Powers holds a bachelor’s degree in chemistry from Wake Forest University, an M.S. in chemical engineering from Clemson University, an M.B.A. from the Duke University Fuqua School of Business and a Ph.D. in biochemical engineering from North Carolina State University.

How old is Johnny Powers?

Johnny Powers is 58, he's been the Independent Director of Zomedica Pharmaceuticals since 2019. There are 4 older and 7 younger executives at Zomedica Pharmaceuticals. The oldest executive at Zomedica Pharmaceuticals Corp. is Robert W. DiMarzo, 64, who is the Consultant.

What's Johnny Powers's mailing address?

Johnny's mailing address filed with the SEC is C/O ZOMEDICA CORP 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR, MI, 48108.

Insiders trading at Zomedica Pharmaceuticals

Over the last 5 years, insiders at Zomedica Pharmaceuticals have traded over $7,040 worth of Zomedica Pharmaceuticals stock and bought 3,375,000 units worth $601,250 . The most active insiders traders include Robert Cohen, Johnny D Powers, and Stephanie Morley. On average, Zomedica Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $39,452. The most recent stock trade was executed by Larry C Ii Heaton on 5 September 2024, trading 100,000 units of ZOM stock currently worth $13,000.

What does Zomedica Pharmaceuticals do?

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Complete history of Johnny Powers stock trades at Idexx Laboratories and Zomedica Pharmaceuticals

Zomedica Pharmaceuticals executives and stock owners

Zomedica Pharmaceuticals executives and other stock owners filed with the SEC include:

• Dr. Stephanie Laine Morley D.V.M., DVM,
  Consultant
• Bruk Herbst,
  Chief Commercial Officer
• Ann Marie Cotter CPA,
  CFO & Sec.
• Rodney Williams,
  Independent Member
• Thomas Robitaille,
  Independent Director
• Johnny Powers,
  Independent Director
• Christopher MacLeod,
  Independent Director
• Jane Eagleson,
  Independent Director
• Christopher Wolfenberg,
  Director
• Angie Moricz,
  Executive Administrative Assistant
• Bruk Herbst,
  Chief Commercial Officer
• Angy Guerrant,
  Director of Portfolio Management
• Andrea Eberle,
  Senior Marketing Manager
• William MacArthur,
  Executive Member and Chief Medical Officer, Director of Research and Development
• Ann Cotter,
  Chief Financial Officer, Secretary
• Robert Cohen,
  Interim Chief Executive Officer, Director
• Stephanie Morley,
  President, Chief Operating Officer
• Jeffrey Rowe,
  Chairman of the Board
• Kristin Domanski,
  VP of HR
• Nicole Westfall,
  VP of Marketing
• Tony Blair,
  Exec. VP of Operations
• Larry C. Heaton II,
  Pres & CEO
• Robert W. DiMarzo,
  Consultant
• Dr. William Carpenter MacArthur,
  Consultant
• David Eaton,
  VP of Marketing
• Michael Schilk,
  VP of Sales
• Sean Whelan,
  
• Russell Kevin Klass,
  Vice President of Sales
• Rampertab Shameze,
  
• James Le Bar,
  Director
• Adrian Lock,
  VP and General Manager
• Larry C Ii Heaton,
  CEO
• Pamela Nichols,
  
• Anthony K Blair,
  COO
• Peter Donato,
  Chief Financial Officer